Picture9.png

INDICAID COVID-19 

RAPID ANTIGEN TEST

PHASE_Scientific_Company_Logo (2).jpg

Authorised for use in Singapore by the Health Science Authority (HSA) under the Pandemic Special Access Route (PSAR) 

The INDICAID® COVID-19 Antigen Rapid Test (ART)
Is a lateral flow immunoassay designed for the qualitative detection of SARS-CoV-2 antigens in direct nasal swab samples. 

INDICAID was developed by PHASE SCIENTIFIC, a Hong Kong biotech company with support from the Bill & Melinda Gates Foundation, National Institutes of Health (NIH), National Science Foundation (NSF) and UCLA. 

blur-coronavirus-2019-ncov-white-background-medical-healthcare-microbiology-concept-design

INTENDED USE

  • Ideal option for the rapid detection of SARS-CoV-2 infection in symptomatic or asymptomatic individuals suspected of infection or in close-contacts with individuals who are COVID-19 positive.

  • Can be used anywhere, anytime by anyone regardless of vaccination or symptom status.

  • Clinically validated with high sensitivity and specificity of 96% and 99% respectively.

  • Proven to be able to detect all COVID-19 variants, including the latest Omicron variant.

DEMO VIDEO

English Language

Cantonese Language

​INSTRUCTION STEPS FOR USE

RESULT INTERPETATION

Picture1.png
2021.09.24-Peoples-Daiily-phasify-01.png

ABOUT PHASE SCIENTIFIC

PHASE Scientific is a high-growth biotech company founded in the United States by Dr Ricky Chiu in 2015. Now headquartered is in Hong Kong,  their global footprint includes R&D, manufacturing  facilities and offices in Southern California, US and Shenzhen, China. 

PHASE Scientific, backed by the Bill and Melinda Gates Foundation, has a patented sample processing technology and aim to bring revolutionary breakthroughs and create changes in health management, focusing on both treatment and prevention.

Bill_&_Melinda_Gates_Foundation_logo.svg.png
nih-logo-color.png
61888cd9044f1e5338f468a5b061ab6e.png
Picture6.png